Integra LifeSciences (NASDAQ:IART) Updates FY 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY 2024 earnings guidance on Monday. The company provided earnings per share guidance of 2.410-2.490 for the period, compared to the consensus earnings per share estimate of 2.450. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. Integra LifeSciences also updated its Q4 guidance to $0.81-0.89 EPS.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $24.91 on Wednesday. The firm has a 50-day simple moving average of $18.68 and a 200-day simple moving average of $24.41. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of 85.90, a price-to-earnings-growth ratio of 0.66 and a beta of 1.08. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. Integra LifeSciences’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.76 EPS. On average, equities analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Truist Financial lowered their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Morgan Stanley raised their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research report on Monday, July 15th. JMP Securities decreased their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a report on Tuesday, July 30th. Finally, Bank of America cut their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Hold” and a consensus target price of $27.25.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.